College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150000, China.
Institute of Opto-Electronics, Harbin Institute of Technology, Harbin 150000, China.
Int J Mol Sci. 2024 May 12;25(10):5267. doi: 10.3390/ijms25105267.
Computational drug-repositioning technology is an effective tool for speeding up drug development. As biological data resources continue to grow, it becomes more important to find effective methods to identify potential therapeutic drugs for diseases. The effective use of valuable data has become a more rational and efficient approach to drug repositioning. The disease-drug correlation method (DDCM) proposed in this study is a novel approach that integrates data from multiple sources and different levels to predict potential treatments for diseases, utilizing support-vector regression (SVR). The DDCM approach resulted in potential therapeutic drugs for neoplasms and cardiovascular diseases by constructing a correlation hybrid matrix containing the respective similarities of drugs and diseases, implementing the SVR algorithm to predict the correlation scores, and undergoing a randomized perturbation and stepwise screening pipeline. Some potential therapeutic drugs were predicted by this approach. The potential therapeutic ability of these drugs has been well-validated in terms of the literature, function, drug target, and survival-essential genes. The method's feasibility was confirmed by comparing the predicted results with the classical method and conducting a co-drug analysis of the sub-branch. Our method challenges the conventional approach to studying disease-drug correlations and presents a fresh perspective for understanding the pathogenesis of diseases.
计算药物重定位技术是加速药物开发的有效工具。随着生物数据资源的不断增长,寻找有效的方法来识别治疗疾病的潜在治疗药物变得更加重要。有效利用有价值的数据已成为药物重定位更合理、更有效的方法。本研究提出的疾病-药物相关性方法(DDCM)是一种新方法,它集成了来自多个来源和不同层次的数据,利用支持向量回归(SVR)来预测疾病的潜在治疗方法。通过构建包含药物和疾病各自相似性的关联混合矩阵,实施 SVR 算法预测关联分数,并进行随机扰动和逐步筛选流程,DDCM 方法为肿瘤和心血管疾病预测了潜在的治疗药物。通过该方法预测了一些潜在的治疗药物。这些药物的潜在治疗能力已经在文献、功能、药物靶点和生存必需基因方面得到了很好的验证。通过与经典方法比较和进行子分支的共同药物分析,验证了该方法的可行性。我们的方法挑战了传统的疾病-药物相关性研究方法,为理解疾病的发病机制提供了新的视角。